A Phase 1 Study of [14C]- IXAZOMIB (MLN9708) to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2017
At a glance
- Drugs Ixazomib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 09 Oct 2015 Planned End Date changed from 1 Aug 2015 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 19 Mar 2015 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reporetd by ClinicalTrials.gov record.